US 12,403,114 B2
Cannabinoid acid ester compositions and uses thereof
Dror Robinson, San Francisco, CA (US); Dan Peer, San Francisco, CA (US); Joseph Tam, Jerusalem (IL); and Raphael Mechoulam, Jerusalem (IL)
Assigned to EPM (IP), INC.; and YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, Jerusalem (IL)
Appl. No. 17/437,780
Filed by EPM (IP), INC., San Francisco, CA (US); and YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, Jerusalem (IL)
PCT Filed Mar. 12, 2020, PCT No. PCT/US2020/022298
§ 371(c)(1), (2) Date Sep. 9, 2021,
PCT Pub. No. WO2020/186010, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/903,848, filed on Sep. 22, 2019.
Claims priority of provisional application 62/903,849, filed on Sep. 22, 2019.
Claims priority of provisional application 62/903,852, filed on Sep. 22, 2019.
Claims priority of provisional application 62/869,568, filed on Jul. 2, 2019.
Claims priority of provisional application 62/856,160, filed on Jun. 3, 2019.
Claims priority of provisional application 62/827,873, filed on Apr. 2, 2019.
Claims priority of provisional application 62/820,302, filed on Mar. 19, 2019.
Claims priority of provisional application 62/816,935, filed on Mar. 12, 2019.
Prior Publication US 2022/0151972 A1, May 19, 2022
Int. Cl. A61K 31/216 (2006.01); A61K 31/352 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/24 (2006.01); A61K 47/40 (2006.01); A61P 1/00 (2006.01); A61P 1/16 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 13/12 (2006.01); A61P 15/00 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01)
CPC A61K 31/216 (2013.01) [A61K 31/352 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/24 (2013.01); A61K 47/40 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 13/12 (2018.01); A61P 15/00 (2018.01); A61P 17/00 (2018.01); A61P 19/02 (2018.01)] 20 Claims
 
1. A pharmaceutical composition comprising a cannabinoid acid ester compound of formula (Ib):

OG Complex Work Unit Chemistry
wherein R1 and R2 are independently selected from C1-C10 alkyl, substituted C1-C10 alkyl, C2-C10 alkenyl, substituted C2-C10 alkenyl, C2-C10 alkynyl, and substituted C2-C10 alkynyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.